OncoMatch/Clinical Trials/NCT06703255
A Phase 2 Study of HX301 in Patients with High-grade Giloma
Is NCT06703255 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies HX301+/Temozolomide for glioma.
Treatment: HX301+/Temozolomide — The study will include a dose-escalation and dose-expansion component to establish the recommended Phase 2 dose (RP2D) for HX301 in combination with Temozolomide and to evaluate the preliminary antitumor activity of HX301.HX301 is an investigational drug that has not yet been approved by the Food and Drug Administration (FDA) or any other regulatory authorities for commercial purposes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage GRADE III, GRADE IV (WHO)
Grade: IIIIV (WHO)
WHO classification grade III or IV
Prior therapy
Must have received: alkylating agent (temozolomide) — Part I: at least one prior temozolomide treatment
Part I: ... At least one prior temozolomide treatment
Must have received: radiation therapy — Part II: standard concurrent chemoradiotherapy (Stupp regimen)
Part II: ... standard concurrent chemoradiotherapy ... according to the Stupp regimen
Cannot have received:
Participation in another study involving an investigational drug within 30 days prior to the first dose of study drug
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify